Newswise — Peritoneal carcinomatosis is a common presentation in gastrointestinal and gynecologic malignancies with limited treatment options. Many patients are offered palliative therapies, but long-term survival and quality of life can be achieved with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland is a leading peritoneal surface malignancy center, specializing in the CRS/HIPEC procedure. Since 1994, Armando Sardi, M.D., FACS, Medical Director, The Institute for Cancer Care at Mercy and Chief, Division of SurgicalOncology, and his colleagues, Vadim Gushchin, M.D., FACS, and Kurtis Campbell, M.D., FACS, have performed more than 800 successful CRS/HIPEC procedures. 

Peritoneal surface malignancies present oncology clinicians with unique challenges and limited treatment options. However, long-term outcomes can be achieved with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The peritoneal surface malignancy program at Mercy Medical Center is proud to be an internationally recognized center in the treatment of peritoneal carcinomatosis with CRS/HIPEC.

This multidisciplinary team is dedicated to advancing breakthrough treatments for cancer management while keeping hope alive through every stage of treatment, recovery, and survivorship. The patient-centered approach is mastered through the combined knowledge and expertise of select surgical, gynecological, medical and radiation oncologists, radiologists, pathologists, primary care physicians, physician assistants, specialized nurses and nurse navigators, registered dietitians, geneticists, and other cancer specialists.

Please access the PDF file for details relevant to Mercy Medical Center’s efforts re: treating peritoneal surface malignancies, as well as utilization of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (CRT/HIPEC) in the treatment of Appendix Cancer, Colorectal Cancer, Ovarian Cancer, Peritoneal Mesothelioma, Gastric Cancer, Rare Cases of Peritoneal Carcinomatosis, and Uterine Sarcoma. For further information, visit The Institute for Cancer Care at Mercy.

MEDIA CONTACT
Register for reporter access to contact details
Download PDF
159491878839782_Mercy_HIPEC CXs.pdf